3896-29-5

Basic information

• Product Name: 2',6'-Difluoroacetanilide
• Synonyms: N-(2,6-DIFLUOROPHENYL)ACETAMIDE;2',6'-DIFLUOROACETANILIDE;2,6-DIFLUOROACETANILIDE;2,6-Difluorophenyl acetamide;2,6-DIFLUOROACETANILIDE, 98% MIN.;N-(2,6-difluorophenyl)ethanamide
• CAS NO: 3896-29-5
• Molecular Formula: C₈H₇F₂NO
• Molecular Weight: 171.14
• Mol File: 3896-29-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 265.9 °C at 760 mmHg
• Flash Point: 114.6 °C
• Appearance: /
• Density: 1.307 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2',6'-Difluoroacetanilide(CAS DataBase Reference)
• NIST Chemistry Reference: 2',6'-Difluoroacetanilide(3896-29-5)
• EPA Substance Registry System: 2',6'-Difluoroacetanilide(3896-29-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 3896-29-5(Hazardous Substances Data)

Usage

General Description

2',6'-Difluoroacetanilide is a chemical compound that is derived from acetanilide, which is an organic compound commonly used in the production of pharmaceuticals and dyes. The addition of two fluorine atoms at the 2' and 6' positions of the acetanilide molecule results in 2',6'-Difluoroacetanilide. This modification can alter the chemical and physical properties of the compound, potentially affecting its reactivity and stability. 2',6'-Difluoroacetanilide may have uses in organic synthesis and medicinal chemistry due to its unique structure, and further research may uncover its potential applications in various fields.

Upstream product

• 3743-95-1 4-Amino-2,6-difluor-acetanilid 
• 3743-92-8 3,5-Difluor-4-amino-azobenzol 
• 5509-65-9 2,6-difluoroaniline 
• 75-36-5 acetyl chloride 
• 3743-87-1 2,6-Difluor-4'-nitro-4-acetamido-azobenzol 
• 3743-89-3 2,6-Difluor-4'-nitro-4-amino-azobenzol 
• 3743-94-0 3,5-Difluor-4-acetamido-azobenzol 
• 3743-90-6 3,5-Difluor-4-amino-acetanilid 
• 3743-86-0 2,6-difluoro-1,4-phenylenediamine 
• 108-24-7 acetic anhydride 
• 103-84-4 Acetanilid 

Downstream Products

• 13800-03-8 N-ethyl-2,6-difluoroaniline 
• 1380229-14-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)benzenesulfonamide 
• 1269421-42-2 N-(3-amino-2,4-difluorophenyl)benzenesulfonamide 
• 1380228-88-5 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)9H-purin-6-yl)pyridin-2-ylamino)phenyl)cyclohexanesulfonamide 
• 1380228-96-5 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)9H-purin-6-yl)pyridin-2-ylamino)phenyl)cyclopropansulfonamide 
• 1380228-67-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)propan-2-sulfonamide 
• 1380228-66-9 N-(3-amino-2,4-difluorophenyl)propane-2-sulfonamide 
• 1380228-80-7 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)propane-1-sulfonamide 
• 1380228-78-3 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)thiophene-2-sulfonamide 

Relevant articles and documents

Preparation method of 2, 4-difluoro-3-nitrobenzoic acid

The invention discloses a preparation method of 2, 4-difluoro-3-nitrobenzoic acid. The preparation method comprises the following technical key points of: carrying out amino protection on 2, 6-difluoroaniline to obtain a compound V; reacting the compound

Regioselective, nucleophilic activation of C&F bonds in o-fluoroanilines

Reactions of ortho-fluorinated anilines with stoichiometric Ti(NMe2)4 in mesitylene (typically for 23 h at 120 °C) afforded moderate to high yields of the corresponding N,N-dimethyl-1,2-phenylenediamine derivatives resulting from def

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling

One of the challenges for targeting B-RafV600E with small molecule inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been associated with hyperplasia in normal tissues. Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E. To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examined the SAR. Three selectivity indices were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochemical (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA). Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivatives. We rationalized this finding based on analysis of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.